SF
ELTX icon

Summit Financial’s Elicio Therapeutics ELTX Stock Holding History

Summit Financial’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.1K Sell
10,005
-5
-0% -$50 ﹤0.01% 1576
2026
Q1 		$107K Hold
10,010
– – ﹤0.01% 1380
2025
Q4 		$79.7K Buy
+10,010
New +$90.8K ﹤0.01% 1276

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Summit Financial's ELTX Position: Q2 2026 in Review

Summit Financial reduced its Elicio Therapeutics (ELTX) stake by 0.05% in Q2 2026, selling an estimated $50 and leaving 10,005 shares worth $39.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1576.

Summit Financial first reported a position in ELTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $107K in Q1 2026. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Summit Financial held 10,005 shares of Elicio Therapeutics worth $39.1K as of Q2 2026.
  • Summit Financial sold 5 Elicio Therapeutics shares in Q2 2026, an estimated $50.
  • Elicio Therapeutics made up ﹤0.01% of Summit Financial's portfolio in Q2 2026, its #1576 holding.
  • Summit Financial first reported a position in Elicio Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Summit Financial's Elicio Therapeutics position peaked at $107K in Q1 2026.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Summit Financial's 13F filing for Q2 2026, filed 12 Aug 2026.